Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that Andrew Hall, Chief Executive Officer will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California....
Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today announced that the first patient has been successfully dosed in its first Phase 1 clinical trial (C-1101-101, NCT07264270) evaluating C-1101 in patients with chronic, painful lumbosacral radiculopathy...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida....
Consano Bio today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College...